Incannex Healthcare Inc. (IXHL): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

-$22.79M
Year ended 2026-06-30
-$19.49M
Trailing 12 months to 2026-09-30
2023-06-30: -$49.58M2024-06-30: -$29.94M2025-06-30: -$23.54M2026-06-30: -$22.79M-$22.79M
2023-06-30 EBITDA (USD) 2026-06-30
Period endedEBITDAChange YoYSource filing
2026-06-30-$22.79Mn/m2026-09-25, From 2025-07-01
2025-06-30-$23.54Mn/m2026-09-25, From 2024-07-01
2024-06-30-$29.94Mn/m2025-09-29, From 2023-07-01
2023-06-30-$49.58Mn/a2024-09-30, From 2022-07-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
Incannex Healthcare Inc. (IXHL)2026-06-30-$22.79Mn/m
TherapeuticsMD, Inc. (TXMD)2025-12-31-$4.01Mn/m
Nature's Sunshine Products Inc (NATR)2025-12-31$38.59M+12.5%
Lisata Therapeutics, Inc. (LSTA)2025-12-31-$18.06Mn/m
Heron Therapeutics, Inc. (HRTX)2025-12-31-$224.0Kn/m
Teva Pharmaceutical Industries Ltd (TEVA)2025-12-31$3.16B+317.9%
Emmaus Life Sciences, Inc. (EMMA)2025-12-31$270.0Kn/m
GeoVax Labs, Inc. (GOVX)2025-12-31-$21.57Mn/m
Lifevantage Corp (LFVN)2026-06-30$8.87M-42.2%

Compare IXHL, TXMD, NATR, LSTA side by side · Screen every company in Pharmaceutical Preparations ↗